Logo image of EYES

SECOND SIGHT MEDICAL PRODUCT (EYES) Stock Fundamental Analysis

USA - NASDAQ:EYES - US81362J3086 - Common Stock

4.14 USD
-0.22 (-5.05%)
Last: 8/30/2022, 8:10:00 PM
4.0921 USD
-0.05 (-1.16%)
After Hours: 8/30/2022, 8:10:00 PM
Fundamental Rating

3

Overall EYES gets a fundamental rating of 3 out of 10. We evaluated EYES against 189 industry peers in the Health Care Equipment & Supplies industry. The financial health of EYES is average, but there are quite some concerns on its profitability. EYES has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

EYES had negative earnings in the past year.
EYES Yearly Net Income VS EBIT VS OCF VS FCFEYES Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -10M -20M -30M

1.2 Ratios

Industry RankSector Rank
ROA -13.82%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EYES Yearly ROA, ROE, ROICEYES Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 1K -1K 2K

1.3 Margins

EYES does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EYES Yearly Profit, Operating, Gross MarginsEYES Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -200 -400 -600 -800

More info and screens

6

2. Health

2.1 Basic Checks

EYES does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EYES has been increased compared to 1 year ago.
EYES has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EYES Yearly Shares OutstandingEYES Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M 10M
EYES Yearly Total Debt VS Total AssetsEYES Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M

2.2 Solvency

An Altman-Z score of 6.02 indicates that EYES is not in any danger for bankruptcy at the moment.
EYES has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.02
ROIC/WACCN/A
WACC9.3%
EYES Yearly LT Debt VS Equity VS FCFEYES Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M 40M 60M

2.3 Liquidity

EYES has a Current Ratio of 22.15. This indicates that EYES is financially healthy and has no problem in meeting its short term obligations.
EYES has a Quick Ratio of 22.15. This indicates that EYES is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 22.15
Quick Ratio 22.15
EYES Yearly Current Assets VS Current LiabilitesEYES Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for EYES have decreased strongly by -42.18% in the last year.
EPS 1Y (TTM)-42.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

EYES is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.08% yearly.
EYES is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 102.94% yearly.
EPS Next Y96.18%
EPS Next 2Y39.88%
EPS Next 3Y25.08%
EPS Next 5YN/A
Revenue Next Year35.73%
Revenue Next 2Y82.84%
Revenue Next 3Y102.94%
Revenue Next 5YN/A

3.3 Evolution

EYES Yearly Revenue VS EstimatesEYES Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
EYES Yearly EPS VS EstimatesEYES Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

EYES reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EYES. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EYES Price Earnings VS Forward Price EarningsEYES Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.22
EYES Per share dataEYES EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

EYES's earnings are expected to grow with 25.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.88%
EPS Next 3Y25.08%

More info and screens

0

5. Dividend

5.1 Amount

EYES does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SECOND SIGHT MEDICAL PRODUCT

NASDAQ:EYES (8/30/2022, 8:10:00 PM)

After market: 4.0921 -0.05 (-1.16%)

4.14

-0.22 (-5.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-30 2022-08-30/amc
Earnings (Next)N/A N/A
Inst Owners0.08%
Inst Owner Change0%
Ins Owners4.53%
Ins Owner Change0%
Market Cap54.38M
Revenue(TTM)N/A
Net Income(TTM)-9.07M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.86
P/tB N/A
EV/EBITDA 0.22
EPS(TTM)-0.69
EYN/A
EPS(NY)-1.37
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS4.8
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.82%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.15
Quick Ratio 22.15
Altman-Z 6.02
F-Score4
WACC9.3%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.46%
EPS Next Y96.18%
EPS Next 2Y39.88%
EPS Next 3Y25.08%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year35.73%
Revenue Next 2Y82.84%
Revenue Next 3Y102.94%
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

SECOND SIGHT MEDICAL PRODUCT / EYES FAQ

Can you provide the ChartMill fundamental rating for SECOND SIGHT MEDICAL PRODUCT?

ChartMill assigns a fundamental rating of 4 / 10 to EYES.


What is the valuation status of SECOND SIGHT MEDICAL PRODUCT (EYES) stock?

ChartMill assigns a valuation rating of 3 / 10 to SECOND SIGHT MEDICAL PRODUCT (EYES). This can be considered as Overvalued.


What is the profitability of EYES stock?

SECOND SIGHT MEDICAL PRODUCT (EYES) has a profitability rating of 2 / 10.


What is the financial health of SECOND SIGHT MEDICAL PRODUCT (EYES) stock?

The financial health rating of SECOND SIGHT MEDICAL PRODUCT (EYES) is 8 / 10.